Cancer drug safety checked in Long-Term study
NCT ID NCT04319198
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 23 times
Summary
This study checked the long-term safety of the drug sacituzumab govitecan in 25 people with metastatic solid tumors (cancer that has spread) who were already benefiting from the treatment. Researchers tracked side effects and lab abnormalities. The goal was to see how safe the drug is when used over a longer period.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Baptist Health - Miami Cancer Institute
Miami, Florida, 33176, United States
-
CHU UCL NAMUR - Sainte Elisabeth
Namur, 5000, Belgium
-
Centre Leon Berard
Lyon, 69373, France
-
Christiana Care Health Services, Christiana Hospital
Newark, Delaware, 19718, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Florida Cancer Specialists & Research Institute
Fort Myers, Florida, 33905, United States
-
Illinois Cancer Specialists
Arlington Heights, Illinois, 60005, United States
-
Institut Bergonie
Bordeaux, 33076, France
-
Institut Claudius Regaud
Toulouse, 31059, France
-
Institut Jules Bordet
Brussels, 1000, Belgium
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
NEXT Oncology
San Antonio, Texas, 78229, United States
-
New York Cancer & Blood Specialists - Setauket Medical Oncology
Port Jefferson, New York, 11776, United States
-
Next Oncology
Austin, Texas, 78758, United States
-
Oncology Consultants,P.A.
Houston, Texas, 77024, United States
-
Rocky Mountain Cancer Center
Aurora, Colorado, 80012, United States
-
The University of Texas M.D. Anderson Cancer Center
Houston, Texas, 77030, United States
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15213, United States
-
University of California San Francisco
San Francisco, California, 94143, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
-
University of MD Greenebaum Comprehensive Cancer Center
Baltimore, Maryland, 21201, United States
Conditions
Explore the condition pages connected to this study.